Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Insmed Incorporated (INSM) brings together the company’s official disclosures to U.S. regulators, offering investors a structured view of its financial condition, material events, and risk factors. As a global biopharmaceutical company focused on serious and rare diseases, Insmed uses filings such as Forms 10-K, 10-Q, and 8-K to report on the performance of its commercial products, the status of its clinical programs, and significant corporate developments.
In periodic reports like the Form 10-K and Form 10-Q, readers can expect detailed discussions of product revenues from therapies such as ARIKAYCE and BRINSUPRI, research and development spending across respiratory, immunology & inflammation, and gene therapy programs, and commentary on liquidity, capital resources, and risks associated with drug development and commercialization. These filings also describe the company’s manufacturing arrangements, intellectual property portfolio, and broader business strategy within pharmaceutical preparation manufacturing.
Current reports on Form 8-K provide timely updates on specific events, including FDA and European Commission approvals of BRINSUPRI, topline clinical results from studies like the Phase 2b BiRCh trial in chronic rhinosinusitis without nasal polyps, and acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory indications. Earnings-related 8-Ks furnish quarterly financial results, while other items may address regulatory milestones, changes in development plans, or key conference presentations.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections of lengthy filings in accessible language. Users can quickly understand how new data or regulatory decisions may affect Insmed’s product portfolio, pipeline, and financial profile, while still having direct access to the underlying EDGAR-sourced documents for deeper analysis.
Insmed Incorporated reported that its Phase 2b CEDAR trial of brensocatib in moderate to severe hidradenitis suppurativa did not meet its primary or secondary efficacy endpoints, and the company will discontinue development of brensocatib for HS.
The randomized, double-blind, placebo-controlled study enrolled 214 patients across 72 global sites. At Week 16, abscess and inflammatory nodule counts fell 45.5% and 40.3% in the 10 mg and 40 mg brensocatib arms, compared with a 57.1% reduction on placebo, indicating no efficacy advantage. Safety was consistent with prior studies, with similar rates of treatment-emergent adverse events and no new safety signals at either dose.
INSM filed a Form 144 reporting proposed sales of Common stock and recent stock-plan related activity. The cover lists a proposed sale date of 04/06/2026 on NASDAQ and identifies William Lewis as the reporting seller. The filing itemizes multiple reported sales by William Lewis dated between 01/06/2026 and 03/19/2026, each with the disclosed reported share counts.
Insmed Inc Chief Operating Officer Roger Adsett exercised options to acquire 88,060 shares of common stock at an exercise price of $14.56 per share. On the same date, he sold 88,060 shares in open-market transactions at weighted average prices of $163.18, $164.11, and $164.95 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. Following these transactions, he directly holds 106,810 shares of Insmed common stock.
INSM Section 144 notice reports proposed sales of Common stock by Roger Adsett. The filing lists four sales dates and share counts: 02/03/2026: 791 shares; 01/08/2026: 2,059 shares; 01/07/2026: 802 shares; 01/06/2026: 1,429 shares. The entries appear under "Securities Sold During The Past 3 Months" and are labeled as Stock Plan Activity.
Insmed Incorporated is asking shareholders to vote at its virtual 2026 annual meeting on three items: electing two Class II directors, an advisory vote on 2025 executive pay, and ratifying Ernst & Young as auditor for 2026.
The company reports 2025 revenue of $606.4 million, driven by ARIKAYCE and the U.S. launch of BRINSUPRI, including a 19% year-over-year increase in global ARIKAYCE revenue and a stock price gain of over 150% in 2025. Insmed highlights a largely independent, skills-diverse Board, strong governance practices, and a pay program that is heavily equity-based and performance-linked, with about 94% of the CEO’s 2025 target direct compensation and 86% of other NEOs’ pay classified as “at risk.”
INSMED Inc Chief Legal Officer Michael Alexander Smith exercised stock options and sold shares in a pre-planned transaction. On March 30, 2026, he exercised options for 19,638 shares of common stock at exercise prices of $17.07 and $27.89 per share. The same day, he sold 19,638 shares of common stock at $150.98 per share under a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, he directly owned 51,871 shares of INSMED common stock.
INSM filing a Form 144 notice reporting proposed sales of Common Stock by an insider. The excerpt lists multiple disposition dates in Q1 2026 and specific lots attributed to Michael Smith, including 24,774 shares on 02/24/2026 and earlier smaller lots in January and February.
Insmed Inc: The Vanguard Group filed an amendment to its Schedule 13G/A reporting beneficial ownership of 0 shares of Common Stock.
The filing explains an internal realignment effective January 12, 2026, that disaggregated certain Vanguard subsidiaries for SEC reporting; the report shows no sole or shared voting or dispositive power over Insmed shares.
Insmed Incorporated reported positive topline results from its Phase 3b ENCORE study of ARIKAYCE in patients with newly diagnosed MAC lung infection not previously treated with antibiotics. ARIKAYCE plus multidrug therapy improved Respiratory Symptom Score at Month 13 by 17.77 points versus 14.66 with placebo, a 3.11‑point advantage (p=0.0299), and achieved culture conversion by Month 6 in 87.8% of patients versus 57.0% with placebo. By Month 15, a significantly greater proportion of ARIKAYCE patients maintained durable culture conversion, and overall study completion exceeded 90% in both arms, with a safety profile consistent with known risks such as dysphonia, cough and bronchospasm. These results fulfill the U.S. FDA post‑marketing requirement, and Insmed plans a supplemental NDA in the second half of 2026 to seek U.S. label expansion and conversion of ARIKAYCE’s existing refractory indication to traditional approval, as well as a parallel submission to Japan’s PMDA.